EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Randomisierte kontrollierte Studie

Pharmacokinetics, pharmacodynamics and safety of LPM3480392 in two phase I clinical trials in healthy Chinese male subjects

Dan-Dan Yang, Jia-Ying Wang iD, Zou-Rong Ruan, Bo Jiang, Yi-Chao Xu, Yin Hu, Xin Che, Yu-Peng Zhang, Hong-Gang Lou

Basic & Clinical Pharmacology & Toxicology · 2023

DOI: 10.1111/bcpt.13937 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Basic & Clinical Pharmacology & Toxicology, 2023. Verfasst von Dan-Dan Yang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Center of Clinical Pharmacology, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China. Hauptthemen laut MEDLINE: Analgesics, Opioid, Receptors, Opioid, mu, Pyridines, Spiro Compounds. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Gefördert von: National Major Science and Technology Projects of China, Luye Pharmaceutical Co. Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Drugs for acute postoperative pain and breakthrough cancer pain are still urgent in clinical. LPM3480392 is a G‐protein‐biased ligand at the μ‐opioid receptor and showed potent analgesia in nonclinical studies. Two phase I studies of LPM3480392 were conducted in healthy Chinese male volunteers to explore its tolerability, pharmacokinetics and pharmacodynamics under single ascending doses (Study I 0.1–3.0 mg, 30 min) and different infusion times (Study II, 0.6–1.0 mg, 2–15 min). There was one serious adverse event (AE) observed in Study II, and the rest AEs were mild or moderate in severity and resolved by the end of the study. Plasma LPM3480392 maximum concentration (C max ) (under lower infusion rate) and area under the plasma concentration‐time curve (AUCs) were generally increased with dose. Moreover, LPM3480392 at a dose of 0.6 mg under a 2 min infusion rate elicited effective analgesia as the peak effect within 10–30 min, which was measured by cold pain test and pupillometry. These findings suggest that LPM3480392 could be a potential treatment for acute pain management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Analgesics, OpioidReceptors, Opioid, muPyridinesSpiro CompoundsAdultHumansMaleYoung AdultArea Under CurveChinaDose-Response Relationship, DrugHealthy VolunteersInfusions, IntravenousEast Asian People

Stichwörter der Autor:innen

LPM3480392analgesiaphase I clinical studyμ-GPS inhibitor

Substanzen

Analgesics, OpioidReceptors, Opioid, muLPM3480392PyridinesSpiro Compounds

Autor:innen und Institutionen

  • Center of Clinical Pharmacology, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
  • Luye Pharmaceutical Co. Ltd., Yantai, Shandong, China.

ORCID-Profile: Jia-Ying Wang

Förderung

  • National Major Science and Technology Projects of China
  • Luye Pharmaceutical Co. Ltd.

Zitieren

APA

Yang, D. D., Wang, J. Y., Ruan, Z. R., Jiang, B., Xu, Y. C., Hu, Y., Che, X., Zhang, Y. P., & Lou, H. G. (2023). Pharmacokinetics, pharmacodynamics and safety of LPM3480392 in two phase I clinical trials in healthy Chinese male subjects. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/bcpt.13937

Vancouver

Yang DD, Wang JY, Ruan ZR, Jiang B, Xu YC, Hu Y, et al. Pharmacokinetics, pharmacodynamics and safety of LPM3480392 in two phase I clinical trials in healthy Chinese male subjects. Basic & Clinical Pharmacology & Toxicology. 2023. doi:10.1111/bcpt.13937

BibTeX
@article{Yang2023,
  author = {Yang, Dan-Dan and Wang, Jia-Ying and Ruan, Zou-Rong and Jiang, Bo and Xu, Yi-Chao and Hu, Yin and Che, Xin and Zhang, Yu-Peng and Lou, Hong-Gang},
  title = {Pharmacokinetics, pharmacodynamics and safety of LPM3480392 in two phase I clinical trials in healthy Chinese male subjects},
  journal = {Basic & Clinical Pharmacology & Toxicology},
  year = {2023},
  doi = {10.1111/bcpt.13937}
}
Kostenlos starten →